医学
放射治疗
食管癌
化疗
肺炎
内科学
随机对照试验
癌症
食管炎
胃肠病学
核医学
肿瘤科
外科
肺
疾病
回流
作者
Yang‐Gun Suh,Ik Jae Lee,Woong Sub Koom,Jae-Young Cha,Jong‐Young Lee,Soo Kon Kim,Chang Geol Lee
出处
期刊:Japanese Journal of Clinical Oncology
[Oxford University Press]
日期:2014-04-24
卷期号:44 (6): 534-540
被引量:59
摘要
In this study, we investigated the effects of radiotherapy ≥60 Gy in the setting of concurrent chemo-radiotherapy for treating patients with Stages II-III esophageal cancer.A total of 126 patients treated with 5-fluorouracilbased concurrent chemo-radiotherapy between January 1998 and February 2008 were retrospectively reviewed. Among these patients, 49 received a total radiation dose of <60 Gy (standard-dose group), while 77 received a total radiation dose of ≥60 Gy (high-dose group). The median doses in the standard- and high-dose groups were 54 Gy (range, 45-59.4 Gy) and 63 Gy (range, 60-81 Gy), respectively.The high-dose group showed significantly improved locoregional control (2-year locoregional control rate, 69 versus 32%, P < 0.01) and progression-free survival (2-year progression-free survival, 47 versus 20%, P = 0.01) than the standard-dose group. Median overall survival in the high- and the standard-dose groups was 28 and 18 months, respectively (P = 0.26). In multivariate analysis, 60 Gy or higher radiotherapy was a significant prognostic factor for improved locoregional control, progression-free survival and overall survival. No significant differences were found in frequencies of late radiation pneumonitis, post-treatment esophageal stricture or treatment-related mortality between the two groups.High-dose radiotherapy of 60 Gy or higher with concurrent chemotherapy improved locoregional control and progression-free survival without a significant increase of in treatment-related toxicity in patients with Stages II-III esophageal cancer. Our study could provide the basis for future randomized clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI